Insight Molecular Diagnostics Inc. — Director's Dealing 2018

Jun 15, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-06-13

Reporting Person: Levine Mitchell S (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-13	Option to Purchase Common Stock	$2.55	A	45000	Acquired	2028-06-12	Common Stock (45000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.35	2028-05-22	Common Stock (50000)	50000	Direct
Option to Purchase Common Stock	$2.35	2028-05-22	Common Stock (125000)	125000	Direct
Option to Purchase Common Stock	$5.90	2027-11-14	Common Stock (200000)	200000	Direct

Footnotes

F1: One half of the options shall vest upon acceptance of the completion of the clinical validation study manuscript for OncoCyte's DetermaVu product candidate, and the balance shall vest upon the start of the clinical utility study for OncoCyte's DetermaVu product candidate.

F2: One quarter of the options shall vest on the one-year anniversary of the grant date and the balance shall vest thereafter in 36 equal monthly installments.

F3: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.

F4: One quarter of the options shall vest on November 14, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.